Literature DB >> 11787877

Anticardiolipin antibodies are not associated with rheumatic heart disease.

H Ilarraza1, M F Márquez, A Alcocer, J L Bañales, A H Nava, P A Reyes.   

Abstract

The aim of this study was to examine the prevalence of anticardiolipin antibodies in rheumatic valve heart disease. Serum samples of 31 consecutive patients with rheumatic heart disease and documented valve involvement, as well as six patients with acute rheumatic fever were tested for IgG anticardiolipin antibodies by a validated ELISA. No anticardiolipin antibodies were found when a cut-off point set at mean +/- 5 s.d. was applied. We can conclude that anticardiolipin antibodies are not present in rheumatic heart disease patients and, as suggested by several observations, these antibodies do not appear to have a pathogenic role in this particular disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11787877     DOI: 10.1191/096120301701548526

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Anti-endothelial cell antibodies in rheumatic heart disease.

Authors:  V Scalzi; H Abu Hadi; C Alessandri; C Croia; V Conti; L Agati; A Angelici; V Riccieri; C Meschini; A Al-Motarreb; A Al-Ansi; G Valesini
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 2.  Infections and the antiphospholipid syndrome.

Authors:  Mario García-Carrasco; Claudio Galarza-Maldonado; Claudia Mendoza-Pinto; Ricardo O Escarcega; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 3.  Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant).

Authors:  Claudia Mendoza-Pinto; Mario García-Carrasco; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2018-08-20       Impact factor: 4.592

Review 4.  Antiphospholipid antibodies in response to infection.

Authors:  Tadej Avcin; Natasa Toplak
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.